Evidence map›Paper›PMID 27890469›Full record

ArticleBiological psychiatry2017

Methamphetamine Addiction Vulnerability: The Glutamate, the Bad, and the Ugly.

Karen K Szumlinski, Kevin D Lominac, Rianne R Campbell, Matan Cohen, Elissa K Fultz, Chelsea N Brown, Bailey W Miller, Sema G Quadir, Douglas Martin, Andrew B Thompson and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Deletion ofFrontiers in pharmacology · 2023
    Article
  19. Article
  20. Substance abuse and neurotransmission.Advances in pharmacology (San Diego, Calif.) · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Karen K SzumlinskiDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California; Molecular, Cellular and Developmental Biology, University of California at Santa Barbara, Santa Barbara, California. Electronic address: karen.szumlinski@psych.ucsb.edu.
Kevin D LominacDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Rianne R CampbellDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Matan CohenDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Elissa K FultzDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Chelsea N BrownDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Bailey W MillerDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Sema G QuadirDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Douglas MartinDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Andrew B ThompsonDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California.
Georg von JonquieresTranslational Neuroscience Facility, School of Medical Sciences, University of New South Wales, New South Wales, Australia.
Matthias KlugmannTranslational Neuroscience Facility, School of Medical Sciences, University of New South Wales, New South Wales, Australia.
Tamara J PhillipsBehavioral Neuroscience and Methamphetamine Abuse Research Center, Oregon Health & Science University; VA Portland Health Care System, Portland, Oregon.
Tod E KippinDepartment of Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, California; Molecular, Cellular and Developmental Biology, University of California at Santa Barbara, Santa Barbara, California; Neuroscience Research Institute, and Institute for Collaborative Biotechnology, University of California at Santa Barbara, Santa Barbara, California.
University of California, Santa Barbara · USUNSW Sydney · AUOregon Health & Science University · US

Funding

Traditional Service Core [Translational Service Core (TSC)]P50DA018165 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2006 to 2016
$13.0M
Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in miceR01DA039168 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BRYANT, CAMRON D · 2015 to 2019
$3.0M
Mouse Genetic Models for Alcohol ResearchR24AA020245 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2011 to 2020
$2.3M
Genetic Risk for Methamphetamine AbuseU01DA041579 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2016 to 2020
$2.1M
Interactions between prenatal stress and genetics in cocaine responsiveness.R01DA027525 · NIDA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KIPPIN, TOD EDWARD · 2010 to 2014
$1.6M
Homer-mediated signaling and cocaine addictionR01DA024038 · NIDA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI SZUMLINSKI, KAREN KATHLEEN · 2008 to 2012
$1.5M
Genetic basis of methamphetamine intakeI01BX002106 · VA · PORTLAND VA MEDICAL CENTER · PI PHILLIPS, TAMARA J. · 2014 to 2022
–
BLRD VA I01 BX002106BLRD VA IK6 BX006342NIAAA NIH HHS R24 AA020245NIDA NIH HHS P50 DA018165NIDA NIH HHS R01 DA024038NIDA NIH HHS R01 DA027525NIDA NIH HHS R01 DA039168NIDA NIH HHS U01 DA041579
6 · The paper itself

Abstract

backgroundThe high prevalence and severity of methamphetamine (MA) abuse demands greater neurobiological understanding of its etiology.

methodsWe conducted immunoblotting and in vivo microdialysis procedures in MA high/low drinking mice, as well as in isogenic C57BL/6J mice that varied in their MA preference/taking, to examine the glutamate underpinnings of MA abuse vulnerability. Neuropharmacological and Homer2 knockdown approaches were also used in C57BL/6J mice to confirm the role for nucleus accumbens (NAC) glutamate/Homer2 expression in MA preference/aversion.

resultsWe identified a hyperglutamatergic state within the NAC as a biochemical trait corresponding with both genetic and idiopathic vulnerability for high MA preference and taking. We also confirmed that subchronic subtoxic MA experience elicits a hyperglutamatergic state within the NAC during protracted withdrawal, characterized by elevated metabotropic glutamate 1/5 receptor function and Homer2 receptor-scaffolding protein expression. A high MA-preferring phenotype was recapitulated by elevating endogenous glutamate within the NAC shell of mice and we reversed MA preference/taking by lowering endogenous glutamate and/or Homer2 expression within this subregion.

conclusionsOur data point to an idiopathic, genetic, or drug-induced hyperglutamatergic state within the NAC as a mediator of MA addiction vulnerability.

Indexed as

AnimalsBehavior, AddictiveGene Knockdown TechniquesGlutamic AcidHomer Scaffolding ProteinsMaleMethamphetamineMiceMice, Inbred StrainsMicrodialysisNucleus AccumbensReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateSelf AdministrationSubstance Withdrawal SyndromeGlutamic AcidHomer2 protein, mouseHomer Scaffolding Proteinsmetabotropic glutamate receptor type 1MethamphetamineReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateConditioned place preferenceGlutamateHomer proteinsMAHDRMetabotropic glutamate receptorNMDA receptorNucleus accumbens

Identifiers

PMID27890469
PMCPMC5391296
OpenAlexW2531266081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.